Technical Analysis for RPRX - Royalty Pharma plc

Grade Last Price % Change Price Change
A 40.1 -0.55% -0.22
RPRX closed up 1.66 percent on Tuesday, January 18, 2022, on 81 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical RPRX trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.02%
Crossed Above 20 DMA Bullish 0.02%
Crossed Above 50 DMA Bullish 0.02%
Calm After Storm Range Contraction 0.02%
Multiple of Ten Bullish Other 0.02%
Fell Below 200 DMA Bearish 1.69%
Fell Below 20 DMA Bearish 1.69%
Fell Below 50 DMA Bearish 1.69%
Calm After Storm Range Contraction 1.69%
Multiple of Ten Bearish Other 1.69%
Older End-of-Day Signals for RPRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown 12 minutes ago
Fell Below 10 DMA 12 minutes ago
Rose Above Previous Day's High about 1 hour ago
Up 1% about 1 hour ago
Up 2% about 21 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Industry Pharmaceutical Products Drug Development HIV Biopharmaceutical Products Biopharmaceutical Industry

Is RPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 53.15
52 Week Low 34.86
Average Volume 2,193,256
200-Day Moving Average 40.04
50-Day Moving Average 39.92
20-Day Moving Average 39.92
10-Day Moving Average 40.13
Average True Range 1.15
ADX 16.96
+DI 26.58
-DI 25.41
Chandelier Exit (Long, 3 ATRs) 39.18
Chandelier Exit (Short, 3 ATRs) 40.93
Upper Bollinger Bands 41.88
Lower Bollinger Band 37.96
Percent B (%b) 0.6
BandWidth 9.83
MACD Line 0.31
MACD Signal Line 0.26
MACD Histogram 0.0518
Fundamentals Value
Market Cap 14.75 Billion
Num Shares 366 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -64.93
Price-to-Sales 12.88
Price-to-Book 5.94
PEG Ratio -0.02
Dividend 0.60
Dividend Yield 1.49%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.37
Resistance 3 (R3) 42.25 41.45 42.03
Resistance 2 (R2) 41.45 40.93 41.51 41.91
Resistance 1 (R1) 40.88 40.60 41.17 41.00 41.80
Pivot Point 40.08 40.08 40.22 40.14 40.08
Support 1 (S1) 39.52 39.56 39.80 39.64 38.84
Support 2 (S2) 38.72 39.24 38.78 38.73
Support 3 (S3) 38.15 38.72 38.61
Support 4 (S4) 38.27